ReviewRSC medicinal chemistry2020
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
Review in RSC medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Structural basis for substrate recognition and inhibition of thioredoxin glutathione reductase from Schistosoma japonicum: Implications for antiparasitic development.PLoS pathogens · 2026Article
- Antischistosomal activity of imidazolidine-2,4-dione derivatives.Antimicrobial agents and chemotherapy · 2026Article
- Discovery and biological evaluation of novelMicrobiology spectrum · 2026Article
- Structure-Activity Relationship of Antischistosomal Aryl Hydantoin (AR102).Journal of medicinal chemistry · 2025Article
- Medicinal Chemistry Progression of Sapanisertib, the Anticancer and DualJournal of medicinal chemistry · 2025Article
- Single-Dose Drug Development Candidate for Schistosomiasis.ACS infectious diseases · 2024Article
- Analysis of the Physicochemical Properties of Anti-Schistosomal Compounds to Identify Next-Generation Leads.ACS medicinal chemistry letters · 2024Article
- New nitazoxanide derivatives: design, synthesis, biological evaluation, and molecular docking studies as antibacterial and antimycobacterial agents.RSC medicinal chemistry · 2023Article
- Design, Synthesis and Evaluation of Praziquantel Analogues and New Molecular Hybrids as Potential Antimalarial and Anti-Schistosomal Agents.Molecules (Basel, Switzerland) · 2023Article
- Investigation of Praziquantel/Cyclodextrin Inclusion Complexation by NMR and LC-HRMS/MS: Mechanism, Solubility, Chemical Stability, and Degradation Products.Molecular pharmaceutics · 2021Article
- Article
- The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species.PLoS neglected tropical diseases · 2021Article
- Inactivation ofMicroorganisms · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, schistosomiasis threatens more than 700 million lives, mostly children, in poor localities of tropical and sub-tropical areas with morbidity due to acute and chronic pathological manifestations of the disease. After a century since the first antimonial-based drugs were introduced to treat the disease, anti-schistosomiasis drug development is again at a bottleneck with only one drug, praziquantel, available for treatment purposes. This review focuses on promising chemotypes as potential starting points in a drug discovery effort to meet the urgent need for new schistosomicides.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.